Cantor Fitzgerald Comments on Theratechnologies Inc.’s FY2024 Earnings (NASDAQ:THTX)

Theratechnologies Inc. (NASDAQ:THTX) – Analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for shares of Theratechnologies in a research report issued to clients and investors on Friday, October 11th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn $0.04 per share for the year, up from their prior forecast of $0.02. The consensus estimate for Theratechnologies’ current full-year earnings is ($0.02) per share.

Theratechnologies Trading Down 0.8 %

THTX stock opened at $1.26 on Monday. The firm has a market capitalization of $57.70 million, a PE ratio of -6.61 and a beta of 1.41. Theratechnologies has a 1-year low of $0.88 and a 1-year high of $2.58. The business’s 50 day simple moving average is $1.27 and its 200 day simple moving average is $1.33.

Theratechnologies (NASDAQ:THTX) last announced its quarterly earnings data on Thursday, October 10th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $22.60 million for the quarter. During the same quarter in the prior year, the company posted ($0.03) EPS.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.